Exagen Inc
XGN
Company Profile
Business description
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Contact
1261 Liberty Way
VistaCA92081
USAT: +1 760 560-1501
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
209
Stocks News & Analysis
stocks
Perplexing buyback from overvalued ASX share
Earnings continue to grow but investor expectations are too high.
stocks
Most popular shares in SMSFs
With data showing the continued rise of SMSFs, we explore the top stock picks of individual investors
stocks
Will China strong arm BHP into lower iron ore prices?
Allegations that the Chinese government told steel mills to stop buying from BHP shake markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,183.30 | 36.30 | -0.39% |
| CAC 40 | 7,934.26 | 16.26 | 0.21% |
| DAX 40 | 24,387.93 | 146.47 | 0.60% |
| Dow JONES (US) | 46,089.14 | 609.54 | 1.34% |
| FTSE 100 | 9,442.87 | 15.40 | 0.16% |
| HKSE | 25,889.48 | 400.84 | -1.52% |
| NASDAQ | 22,691.76 | 487.33 | 2.19% |
| Nikkei 225 | 48,088.80 | 491.64 | -1.01% |
| NZX 50 Index | 13,351.92 | 115.34 | -0.86% |
| S&P 500 | 6,658.31 | 105.80 | 1.61% |
| S&P/ASX 200 | 8,882.80 | 36.30 | -0.41% |
| SSE Composite Index | 3,889.50 | 7.53 | -0.19% |